BDX

Over the past six months, BDX stock has been impacted by several events: In May 2026, BD announced solid Q2 FY26 earnings, beating estimates for EPS and revenue, which led to a nearly 6% stock price increase on the day of the release. In February 2026, BD spun off its biosciences and diagnostic solutions division to Waters Corp., with BD shareholders receiving a stake in Waters and BD receiving $4 billion in cash, intended for stock repurchases and debt repayment. In August 2026, BDX shares closed up by 3.8% after reporting Q3 FY26 results that exceeded Wall Street expectations for both adjusted EPS and revenue. In October 2026, BD announced a landmark partnership with the U.S. Government, committing to invest $19 billion in the United States, including $3 billion for manufacturing expansion, to increase domestic production capacity. Also in October 2026, Barclays initiated coverage on Becton Dickinson with an 'Underweight' rating and a price target of $165.00, suggesting a cautious outlook.